Physician profile
Annabel Wallace
NPI 1063973840
$649.27
in general payments reported to CMS, 2019-2025
14 companies · $258 in 2025
The $258 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $28.58 · 2024: $363 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $549 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $549.28 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $171.03 | 2024-2025 | Tremfya |
| Ucb, INC. | $95.84 | 2024-2025 | Bimzelx, Cimzia |
| Amgen INC. | $79.16 | 2024 | Prolia, Evenity, Enbrel |
| Aurinia Pharma U.S., INC. | $56.36 | 2023-2024 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $35.34 | 2024-2025 | |
| Abbvie INC. | $29.67 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.68 | 2024 | Spevigo |
| Organon LLC | $26.80 | 2025 | Hadlima, Renflexis |
| Kiniksa Pharmaceuticals International, Plc | $24.16 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $23.04 | 2025 | Saphnelo |
| Glaxosmithkline, LLC. | $22.19 | 2025 | Benlysta |
| Alexion Pharmaceuticals, INC. | $21.97 | 2025 | Strensiq |
| Fresenius Kabi USA, LLC | $18.01 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $17.02 | 2024 | Orencia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annabel Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.